Sign-up for our newsletter
MAIN
Event Calendar
Awardee Reports
ABOUT DIACOMP
Citing DiaComp
Contact
Committees
Institutions
Awardee Reports
Funding Programs
Pilot & Feasibility
Conference Support
Summer Student
Collaborative
External Funding Programs
Publications
Bioinformatics
RESOURCES
Protocols & Methods
Reagents & Resources
Mouse Diet
Breeding Schemes
Validation Criteria
IMPC / KOMP Data
Publications
Bioinformatics
FUNDING PROGRAMS
Pilot & Feasibility
Conference Support
Summer Student
Collaborative
External Funding Programs
CONTACT
PARTICIPANT AREA
Login
Request Account
▹
DiaComp Funded Abstracts
Program Application Abstract
Increased Plasma Caveolin-1 Reflects Insulin Resistance and Vascular Dysfunction in Type 2 Diabetes.
Hyde, George
(University of Michigan-Ann Arbor)
Mentor: Haus, Jacob M. (University of Michigan)
Summer Student Program
It is generally accepted that caveolin-1 (Cav-1) functions to regulate endothelial nitric oxide synthase (eNOS) by repressing eNOS activity via direct binding and that both increased eNOS activity and reduced Cav-1 expression play a role in the pathology of vascular disease. Further, studies exploring Cav-1 regulation under conditions of oxidative stress (OS) have concluded that OS promotes Cav-1 phosphorylation and accumulation in the monomeric form. Following monomerization, Cav-1 is targeted for ubiquitinoylation and degradation by the proteasome and undergoes exocytosis, thus indicating that increased plasma appearance of Cav-1 indicates cellular Cav-1 degradation. We have previously demonstrated reduced endothelial Cav-1 and increased eNOS activity with concomitant impaired microvascular function, reduced nitric oxide bioavailability in tissue biopsies from type 2 diabetes patients (T2D). The mechanisms by which repeated pathophysiological insults such as insulin resistance and compensatory hyperinsulinemia evolve into endothelial dysfunction and vascular disease are needed to better understand the causes, and to identify, novel treatment strategies for cardiovascular disease. Thus, we tested the hypothesis that experimental hyperinsulinemia would induce an increase in plasma Cav-1 and that plasma Cav-1 under these conditions would correlate with the degree of insulin resistance and markers of OS and inflammation. We enrolled 10 lean healthy (BMI: 18-25 kg/m2) controls and 9 obese (BMI: 26-40 kg/m2) T2D men and women aged between 18 – 70 years. Blood was taken from each participant following an overnight fast (10-12 h) and during the steady-state periods of a hyperinsulinemic (40 mU/m2/min)-euglycemic (90 mg/dL) clamp procedure where glucose disposal rates were also derived. Plasma Cav-1 (ng/mL) was measured via ELISA. A significant group effect (LHC v. T2D) was found for plasma Cav-1 (F=50.12, p < 0.001). In addition, when compared to LHC, there was a significant increase in plasma Cav-1 (T2D: 0.60±0.41 basal; 0.80±0.19 insulin, LHC: 0.65±1.27 basal; 0.34±0.17 insulin, p=0.003) after insulin stimulation. Inverse correlations were found between plasma Cav-1 and clamp-derived glucose disposal rates (R= -0.71, p=0.03), whereas positive correlations (p<0.05) were found between plasma Cav-1 and age, fasting glucose, TBARS and TNF-alpha. In summary, these data demonstrate an insulin-stimulated dynamic between plasma Cav-1 and mediators of cardiometabolic health and support a role for plasma Cav-1 as a viable biomarker for microvascular dysfunction. A better understanding of the inflammatory response associated with chronic vascular disease will be critical for developing new therapeutic approaches, enabling early diagnosis, and for creation of more efficient treatments that rescue endothelial cell Cav-1 expression and vascular homeostasis.
Welcome to the DiaComp Login / Account Request Page.
Email Address:
Password:
Note: Passwords are case-sensitive.
Please save my Email Address on this machine.
Not a member?
If you are a funded DiaComp investigator, a member of an investigator's lab,
or an external advisor to the consortium, please
request an account.
Forgot your password?
Enter your Email Address and
click here.
ERROR!
There was a problem with the page:
User Info
User Confirm
Safari Browser Detected...
We strive to make the DiaComp site compatable with as many browsers as possible, but some of our third party tools don't work with the Safari browser.
In order to explore this site we highly recommend using the most recent versions of the following browsers:
Internet Explorer
Google Chrome
FireFox
Please acknowledge all posters, manuscripts or scientific materials that were generated in part or whole using funds from the Diabetic Complications Consortium(DiaComp) using the following text:
Financial support for this work provided by the NIDDK Diabetic Complications Consortium (RRID:SCR_001415, www.diacomp.org), grants DK076169 and DK115255
Citation text and image have been copied to your clipboard. You may now paste them into your document. Thank you!